FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
ES2202310T3
(es)
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
ATE401348T1
(de)
|
1999-05-27 |
2008-08-15 |
Us Gov Health & Human Serv |
Immunokonjugate mit hoher bindungsaffinität
|
WO2001029058A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
WO2001062895A2
(en)
|
2000-02-24 |
2001-08-30 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
WO2002002621A2
(en)
|
2000-06-30 |
2002-01-10 |
Zymogenetics, Inc. |
Mammalian secreted proteins
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
AU2003208839A1
(en)
|
2002-02-13 |
2003-09-04 |
Micromet Ag |
De-immunized (poly)peptide constructs
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
JP2006524036A
(ja)
|
2002-11-08 |
2006-10-26 |
アブリンクス エン.ヴェー. |
腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
US7251470B2
(en)
|
2003-06-25 |
2007-07-31 |
Nokia Corporation |
Emergency response system with personal emergency device
|
JP5026072B2
(ja)
|
2003-07-01 |
2012-09-12 |
イミューノメディクス、インコーポレイテッド |
二重特異性抗体の多価キャリヤー
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
EP2272566A3
(en)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisation of antibodies
|
EP1660534A2
(en)
|
2003-08-22 |
2006-05-31 |
MedImmune, Inc. |
Humanization of antibodies
|
KR101229731B1
(ko)
|
2003-10-16 |
2013-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
다중특이적 탈면역화된 cd3-바인더
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
US20080294058A1
(en)
|
2004-08-16 |
2008-11-27 |
Dror Shklarski |
Wearable Device, System and Method for Measuring a Pulse While a User is in Motion
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
AU2006223301B2
(en)
|
2005-03-10 |
2010-11-04 |
Eisai, Inc. |
Anti-mesothelin antibodies
|
US20090047211A1
(en)
|
2005-05-12 |
2009-02-19 |
The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services |
Anti-mesothelin antibodies useful for immunological assays
|
RU2515108C2
(ru)
|
2005-08-19 |
2014-05-10 |
Эббви Инк |
Иммуноглобулин с двойными вариабельными доменами и его применения
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AU2008233051B2
(en)
|
2007-03-30 |
2014-04-10 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
US9023351B2
(en)
|
2007-11-26 |
2015-05-05 |
Bayer Intellectual Property Gmbh |
Anti-mesothelin antibodies and uses thereof
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
KR20090092900A
(ko)
|
2008-02-28 |
2009-09-02 |
신준호 |
어린이 및 노약자 안전보호시스템
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
US20090322513A1
(en)
|
2008-06-27 |
2009-12-31 |
Franklin Dun-Jen Hwang |
Medical emergency alert system and method
|
US8822647B2
(en)
|
2008-08-26 |
2014-09-02 |
City Of Hope |
Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
|
RU2547600C2
(ru)
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
KR101695327B1
(ko)
|
2008-11-07 |
2017-01-11 |
암젠 리서치 (뮌헨) 게엠베하 |
급성 림프구성 백혈병의 치료방법
|
CN104877026B
(zh)
|
2009-03-10 |
2019-10-25 |
比奥根Ma公司 |
抗-bcma抗体
|
AU2010238723A1
(en)
|
2009-04-23 |
2011-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
EP2258719A1
(en)
|
2009-05-19 |
2010-12-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Multiple target T cell receptor
|
ES2649890T3
(es)
|
2009-10-23 |
2018-01-16 |
Nexisvision, Inc. |
Enervación corneal para el tratamiento de dolor ocular
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
PL2361936T3
(pl)
|
2010-02-25 |
2016-10-31 |
|
Cząsteczka wiążąca antygen i jej zastosowania
|
EP3222632A1
(en)
|
2010-03-26 |
2017-09-27 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
WO2012008860A2
(en)
|
2010-07-16 |
2012-01-19 |
Auckland Uniservices Limited |
Bacterial nitroreductase enzymes and methods relating thereto
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
DK2632954T4
(da)
|
2010-10-27 |
2021-08-09 |
Amgen Res Munich Gmbh |
Midler og fremgangsmåder til behandling af dlbcl
|
WO2012075158A1
(en)
|
2010-12-01 |
2012-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ror1 antibodies
|
KR102062407B1
(ko)
|
2010-12-09 |
2020-01-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
MX345519B
(es)
|
2010-12-20 |
2017-02-01 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados.
|
WO2012097313A2
(en)
|
2011-01-14 |
2012-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
SG192010A1
(en)
|
2011-01-18 |
2013-08-30 |
Univ Pennsylvania |
Compositions and methods for treating cancer
|
JP5955871B2
(ja)
|
2011-03-17 |
2016-07-20 |
ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Tcrアルファ/ベータを枯渇させた細胞調製物
|
EP2694549B1
(en)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
ES2861435T3
(es)
|
2011-11-03 |
2021-10-06 |
Univ Pennsylvania |
Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
ES2774160T3
(es)
|
2012-02-13 |
2020-07-17 |
Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute |
Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
|
CN104159909A
(zh)
|
2012-02-22 |
2014-11-19 |
宾夕法尼亚大学董事会 |
产生用于癌症治疗的t细胞持续性群体的组合物和方法
|
JP2015509716A
(ja)
|
2012-02-22 |
2015-04-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
第二世代キメラ抗原受容体におけるcd2シグナル伝達ドメインの使用
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CA2869562C
(en)
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
US20130280220A1
(en)
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
EP3964567A1
(en)
|
2012-05-25 |
2022-03-09 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
ES2733525T3
(es)
|
2012-07-13 |
2019-11-29 |
Univ Pennsylvania |
Métodos para evaluar la adecuación de los linfocitos T transducidos para su administración
|
MX2015000426A
(es)
|
2012-07-13 |
2015-07-14 |
Univ Pennsylvania |
Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
|
AU2013305838A1
(en)
|
2012-08-20 |
2015-02-26 |
Fred Hutchinson Cancer Center |
Method and compositions for cellular immunotherapy
|
CA2885761C
(en)
|
2012-09-27 |
2021-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055668A1
(en)
|
2012-10-02 |
2014-04-10 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Bcmaに対する抗体の選択のための方法
|
NZ750426A
(en)
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
PT3300745T
(pt)
|
2013-02-15 |
2019-11-27 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
KR102363191B1
(ko)
|
2013-02-26 |
2022-02-17 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
CA2902954A1
(en)
|
2013-03-01 |
2014-09-04 |
Regents Of The University Of Minnesota |
Talen-based gene correction
|
EP2964675B1
(en)
|
2013-03-05 |
2018-06-20 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
KR102466666B1
(ko)
|
2013-03-15 |
2022-11-15 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
AU2014248119B2
(en)
|
2013-04-03 |
2019-06-20 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
KR102248157B1
(ko)
|
2013-05-13 |
2021-05-03 |
셀렉티스 |
Cd19 특이적 키메라 항원 수용체 및 이의 용도
|
EP3004168A4
(en)
|
2013-05-24 |
2017-03-01 |
Board of Regents, The University of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
US9890393B2
(en)
|
2013-05-29 |
2018-02-13 |
Cellectis |
Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
|
RU2016104130A
(ru)
|
2013-07-12 |
2017-08-17 |
Займворкс Инк. |
Биспецифичные конструкции, связывающие антигены cd3 и cd19
|
US9879218B2
(en)
|
2013-08-01 |
2018-01-30 |
Fermentalg |
Methods for the production of diatom biomass
|
AU2014296059B2
(en)
|
2013-08-02 |
2020-12-10 |
The Regents Of The University Of California |
Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
AU2014368383B2
(en)
|
2013-12-20 |
2020-01-16 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
MY178233A
(en)
|
2013-12-20 |
2020-10-07 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
JP6706578B2
(ja)
|
2013-12-30 |
2020-06-10 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Fab免疫グロブリン及びその使用
|
JP2017507917A
(ja)
|
2014-01-14 |
2017-03-23 |
セレクティスCellectis |
軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体
|
EP4303229A3
(en)
*
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
EP3097123A1
(en)
|
2014-01-24 |
2016-11-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
|
KR20160113295A
(ko)
|
2014-02-04 |
2016-09-28 |
카이트 파마 인코포레이티드 |
B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
|
MX2016010128A
(es)
*
|
2014-02-07 |
2017-02-02 |
Univ Mcmaster |
Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
|
PT3105317T
(pt)
|
2014-02-14 |
2019-02-27 |
Cellectis |
Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
|
EP3105335B1
(en)
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
AU2015220762B2
(en)
|
2014-02-21 |
2019-05-02 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
DK3514172T3
(da)
|
2014-04-01 |
2020-04-06 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-6-specifikke immunoreceptorer og t-celleepitoper
|
AU2015248956B2
(en)
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
DK3134095T3
(da)
|
2014-04-25 |
2020-06-29 |
Bluebird Bio Inc |
Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
|
CA2984484C
(en)
|
2014-05-02 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
WO2015177349A1
(en)
|
2014-05-23 |
2015-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- egfr conformational single domain antibodies and uses thereof
|
WO2015179801A1
(en)
|
2014-05-23 |
2015-11-26 |
University Of Florida Research Foundation, Inc. |
Car based immunotherapy
|
EP4166148A1
(en)
|
2014-06-06 |
2023-04-19 |
Memorial Sloan-Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
CN106687483B
(zh)
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
使用人源化抗-bcma嵌合抗原受体治疗癌症
|
JP6706244B2
(ja)
|
2014-07-24 |
2020-06-03 |
ブルーバード バイオ, インコーポレイテッド |
Bcmaキメラ抗原受容体
|
JP6721568B2
(ja)
|
2014-07-29 |
2020-07-15 |
セレクティスCellectis |
がん免疫療法のためのror1(ntrkr1)特異的キメラ抗原レセプター
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
US9994817B2
(en)
|
2014-08-07 |
2018-06-12 |
Northwestern University |
Use of ligands for the programmed cell death receptor conjugated to solid supports for cultivating human regulatory T cells
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
US10800830B2
(en)
|
2014-08-08 |
2020-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
CA2957929A1
(en)
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
AU2015308818B2
(en)
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
CN107074969A
(zh)
|
2014-09-09 |
2017-08-18 |
优努姆治疗公司 |
嵌合受体及其在免疫治疗中的应用
|
BR112017005631A2
(pt)
|
2014-09-19 |
2018-06-26 |
City Of Hope |
células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
|
WO2016054520A2
(en)
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
AU2015330017A1
(en)
|
2014-10-07 |
2017-04-27 |
Cellectis |
Method for modulating car-induced immune cells activity
|
ES2879612T3
(es)
|
2014-10-20 |
2021-11-22 |
Juno Therapeutics Inc |
Métodos y composiciones para dosificación en terapia celular adoptiva
|
WO2016070061A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified t cells
|
EP3215139B1
(en)
|
2014-11-03 |
2020-08-19 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
MA40318A
(fr)
|
2014-11-05 |
2017-09-13 |
Juno Therapeutics Inc |
Procédés de transduction et de traitement de cellules
|
PL3221357T3
(pl)
|
2014-11-20 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Wspólne łańcuchy lekkie i sposoby zastosowania
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
MX2017007138A
(es)
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Metodos y composiciones para terapia celular adoptiva.
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
EP4310097A3
(en)
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
PL3227339T3
(pl)
|
2014-12-05 |
2022-02-21 |
Memorial Sloan-Kettering Cancer Center |
Chimeryczne receptory antygenowe ukierunkowane na receptory sprzężone białka g oraz ich zastosowania
|
AU2015367317A1
(en)
|
2014-12-17 |
2017-06-01 |
Cellectis |
Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
|
EP3037170A1
(en)
|
2014-12-27 |
2016-06-29 |
Miltenyi Biotec GmbH |
Multisort cell separation method
|
KR20170093254A
(ko)
|
2014-12-29 |
2017-08-14 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
EP3245227A4
(en)
|
2015-01-14 |
2018-07-25 |
Compass Therapeutics LLC |
Multispecific immunomodulatory antigen-binding constructs
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
GB201501175D0
(en)
|
2015-01-23 |
2015-03-11 |
Univ Oslo Hf |
A universal T-cell for personalised medicine
|
JP6912386B2
(ja)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なIL13Rα2を認識するCAR T細胞
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
WO2016127043A1
(en)
|
2015-02-05 |
2016-08-11 |
Stc.Unm |
Anti-pre-bcr antagonists and methods
|
AU2016214978B2
(en)
|
2015-02-05 |
2021-12-09 |
The University Of Queensland |
Targeting constructs for delivery of payloads
|
US20160228547A1
(en)
|
2015-02-06 |
2016-08-11 |
Batu Biologics, Inc. |
Chimeric antigen receptor targeting of tumor endothelium
|
WO2016127257A1
(en)
|
2015-02-12 |
2016-08-18 |
University Health Network |
Chimeric antigen receptors
|
US20160237407A1
(en)
|
2015-02-17 |
2016-08-18 |
Batu Biologics, Inc. |
Universal donor chimeric antigen receptor cells
|
IL297418B2
(en)
|
2015-02-18 |
2023-11-01 |
Enlivex Therapeutics Rdo Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
JP6784687B2
(ja)
|
2015-02-24 |
2020-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
結合誘発型転写スイッチ及びその使用方法
|
CN107073138B
(zh)
|
2015-03-02 |
2018-06-29 |
上海斯丹赛生物技术有限公司 |
降低由pd-l1诱导的免疫耐受性
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
AU2016243043B2
(en)
|
2015-04-02 |
2021-12-09 |
Memorial Sloan Kettering Cancer Center |
TNFRSF14/ HVEM proteins and methods of use thereof
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
HUE054201T2
(hu)
|
2015-06-19 |
2021-08-30 |
Endres Stefan Prof Dr |
PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JP6816133B2
(ja)
|
2015-10-05 |
2021-01-20 |
プレシジョン バイオサイエンシズ,インク. |
改変ヒトt細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
MA43816A
(fr)
|
2016-03-08 |
2018-11-28 |
Maverick Therapeutics Inc |
Protéines de liaison inductibles et méthodes d'utilisation
|
SI3436079T1
(sl)
|
2016-04-01 |
2022-01-31 |
Kite Pharma, Inc. |
Himerni antigen in T celični receptorji ter način uporabe
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
JP2019528051A
(ja)
|
2016-07-21 |
2019-10-10 |
ディヴェロップメント センター フォー バイオテクノロジー |
修飾抗原結合Fab断片及びこれを含む抗原結合分子
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
AU2017382902A1
(en)
|
2016-12-21 |
2019-07-18 |
TCR2 Therapeutics Inc. |
Engineered T cells for the treatment of cancer
|
AU2018231127A1
(en)
|
2017-03-09 |
2019-09-19 |
Cytomx Therapeutics, Inc. |
CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
|
CA3059753A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
KR102376863B1
(ko)
|
2017-05-12 |
2022-03-21 |
하푼 테라퓨틱스, 인크. |
메소텔린 결합 단백질
|
JP7209936B2
(ja)
|
2017-05-12 |
2023-01-23 |
ハープーン セラピューティクス,インク. |
Msln標的三重特異性タンパク質及びその使用方法
|
US20210079057A1
(en)
|
2017-06-13 |
2021-03-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20210361704A1
(en)
|
2018-03-09 |
2021-11-25 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2019222275A2
(en)
|
2018-05-14 |
2019-11-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using inducible fusion proteins
|
MX2021001009A
(es)
|
2018-07-26 |
2021-07-02 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
|
SG11202101811VA
(en)
|
2018-08-30 |
2021-03-30 |
Tcr2 Therapeutics Inc |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2020061526A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|